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Abstract: We report on a 30-year-old patient with advanced
cerebellar degeneration due to SCA2. He presented with severe
myoclonus, which was resistant to conventional therapy and
dramatically improved after administration of 12–18 gm/die
piracetam. Piracetam may be considered in the treatment of
refractory myoclonus in spinocerebellar degenerations. © 2005
Movement Disorder Society
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Spinocerebellar ataxia type 2 (SCA2) is one of the most fre-
quent among the autosomal dominant cerebellar ataxias and the
most common in Italy. An abnormally expanded cytosine-
adenine-guanine (CAG) triplet sequence has been found within
a gene encoding for ataxin-2, a protein of unknown function.1
The main clinical features of SCA2 are gait and limb ataxia,
dysarthria, supranuclear ophthalmoplegia, and peripheral neu-
ropathy. Myoclonus is infrequent in SCA2 and usually present
in late disease stages, whereas it is a typical clinical feature of
other dominant ataxias such as DRPLA, SCA14, and SCA19.2
Piracetam (2-oxo-1-pyrrolidine-acetamide) at high doses is
an effective and well-tolerated drug for treatment of myoclo-
nus.3,4 We describe an SCA2 patient who developed a severe
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TABLE 1. Pre- and posttreatment scores for patients randomized to tegaserod or placebo
Tegaserod Placebo
P for
changePre Post Pre Post
Total SGA 9.1 4.4 8.3  4.0 6.2  3.7 8.7  3.9 .10
Bothersome constipation 3.3  2.0 2.8  1.7 2.2  1.5 3.0  1.5 .14
SGA of abdominal pain and discomfort 2.8 1.5 2.5  1.4 1.7  1.9 2.7  1.5 .30
SGA of satisfaction 3.1  1.1 3.0  1.1 2.3  1.0 3.0  1.1 .10
UPDRS 42.1  22.5 39.8  25.7 33.8  10.4 37.0  11.6 .32
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multifocal myoclonus in a late stage of the disease. Piracetam
administration dramatically improved myoclonus.
Case Report
This 30-year-old man was affected by SCA2, conﬁrmed by
molecular diagnosis (46/22 CAG triplets). His 57-year-old fa-
ther (37/22 CAG triplets) did not report any complaint but the
neurological examination showed mild dysarthria as well as
gait and limb ataxia. The disease onset was at 17 years of age
with mild dysarthria, dizziness, gait ataxia, and clumsiness. A
brain MRI showed marked atrophy of cerebellar hemispheres,
vermis, and pons. The clinical picture worsened rapidly and
severe dysphagia both for solids and liquids developed. The
patient was admitted to our department for aspiration pneumo-
nia and a percutaneous endoscopic gastrostomy (PEG) was
performed.
Neurological examination showed mild drowsiness, impos-
sible stance and gait, anarthria, intention tremor, dysmetria,
slowness of saccadic eye movements, weakness, hypotrophy
and increased tone in all limbs, reduced tendon reﬂexes, dys-
tonic movements, and severe continuous multifocal myoclonus.
Myoclonus was markedly worsened by movement (see Video,
Segment 1), pinprick, or passive stretch. International Cooper-
ative Ataxia Rating Scale (ICARS) score was 97/100.5 Neuro-
psychological evaluation was impossible due to the severe
cognitive decline.
Video polygraphic examination showed irregular high-
amplitude continuous and multifocal myoclonus, more evi-
dent at the upper limbs with diffuse slowing of background
activity and no paroxysmal activity at EEG. Surface EMG
recording from the wrist extensor and ﬂexor and biceps
brachii revealed muscle jerks lasting approximately 40 to 60
msec with no synchronous agonist and antagonist muscle
involvement. Jerk-locked back-averaging analysis did not
demonstrate any EEG–EMG correlate. It was not possible to
perform somatosensory evoked potentials (SEPs) and Long
Loop Reﬂex I (C-reﬂex) because of the muscular artifacts
and the patient’s poor cooperation.
Valproate (30 mg/kg/die) and clonazepam (0.1 mg/kg/die)
oral administration only resulted in partial and transient
suppression of involuntary muscle jerks. Levetiracetam (60
mg/kg/die) at a daily dosage of 3,000 mg for 2 months was
also ineffective. Then, we administered 12 gm of piracetam
(240 mg/kg/die) by rapid intravenous bolus once a day for a
week. After 1 day, we observed a dramatic reduction of
myoclonus, which almost disappeared within 3 days. The
patient also appeared more alert. No clinical beneﬁt on the
other neurological symptoms was obtained. The beneﬁt
lasted approximately 48 hours after drug discontinuation.
The reintroduction of piracetam rapidly induced the disap-
pearance of the myoclonus again. In concomitance of a
febrile illness, we observed reappearance of myoclonus,
which was successfully treated, increasing the dose to 18 gm
once a day. After 3 months of IV treatment, piracetam was
administered by PEG at the daily dose of 18 with no beneﬁt
loss. Due to difﬁculty to get drug supply, it was withdrawn
on two occasions and marked myoclonus reappeared. To
date, after 1 year of treatment, the patient is myoclonus-free
(see Video, Segment 2) with neither side effects nor routine
blood test changes.
Discussion
Myoclonus is an infrequent and usually late symptom in
SCA2 patients and its origin is still unclear. Neurophysiological
studies suggested that myoclonus may be of brainstem or spinal
origin in SCA14,6 whereas both cortical and spinal myoclonus
have been described in SCA19.7 In our case, the origin of
myoclonus is not very clear because it was not possible to
perform a complete electrophysiological study before pira-
cetam (PIR) treatment. In cortical myoclonus, EEG recording
may show variable paroxysmal abnormalities, usually consist-
ing of multifocal or generalized spike-and-wave discharge.8
Surface EMG recording reveals a burst duration less than 75
msec.9 Jerk-locked back-averaging discloses a focal and central
positive–negative biphasic spike that precedes the jerk onset by
10 to 40 msec.8,9 In our patient, we did not detect paroxysmal
EEG activity and surface EMG recording revealed a muscle
jerk lasting 40 to 60 msec, not correlated to EEG. Stimulus
sensitivity and burst duration may be consistent with cortical
myoclonus, but the absence of EEG abnormalities and jerk-
locked back-averaging results are against this hypothesis. The
electrophysiological data may suggest a myoclonus of subcor-
tical origin, usually characterized by burst of variable duration
and no EMG–EEG correlate.9 The disturbance seems to differ
from minipolymyoclonus that is characterized by subtle and
recurring twitches predominant in the ﬁngers and hands with
simultaneous discharges in antagonist muscles of the same limb
and bilateral synchronous jerks of homologous muscles, corre-
lated to bilateral synchronous frontocentral potentials.10
Piracetam, a low-molecular-weight derivative of -aminobu-
tyric acid (GABA), has been widely used to treat cognitive
disorders as nootropic agent and myoclonus.3,4 It is tradition-
ally considered quite safe in terms of side effects. However,
gastric discomforts, diarrhea, and hematological abnormalities
may sometimes occur, especially at high doses.3,4 Piracetam is
present in the polar heads of phospholipid membrane models
and it is thought to alter the physical properties and the ﬂuidity
of the brain cell membranes.11,12 In our patient, piracetam was
effective on myoclonus at daily doses of 12–18 per day,
whereas levetiracetam was not at the daily IV dose of 3,000
mg. This could be explained by the different mechanism of
action of the drugs12 or by the need to reach a higher leveti-
racetam dose.13
Piracetam at high dose (60 g/die) improved gait ataxia in a
patient with degenerative cerebellar ataxia without myoclonus.
The effect was fast and lasted approximately 1 month after
discontinuation of the drug.14 Conversely, in our case, pirac-
etam improved only myoclonus and its effect only lasted few
days after drug withdrawal. The baseline condition was much
more severe and the cerebellar atrophy at a more advanced
stage in our patient. We observed improved alertness, possibly
due to the nootropic effect of piracetam or due to the with-
drawal of clonazepam. In conclusion, the good tolerability of
piracetam makes it easy to test for treatment of refractory and
disabling myoclonus in SCA patients.
Legends to the Video
Segment 1. Baseline condition. Neurological examina-
tion shows diffuse, irregular, and continuous myoclonic
jerks worsened by movement. Repetitive, pseudorhythmic,
not voluntary movements of the ﬁngers are also evident.
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Segment 2. After 1 year of therapy with piracetam,
18 g/day, both rest and action myoclonus are clearly
reduced and the patients appears more alert. Dysmetria
and dystonic neck and trunk posture are evident.
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Sporadic Rapid-Onset Dystonia–Parkinsonism
Presenting as Parkinson’s Disease
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Abstract: We report on a 38-year-old patient with rapid-onset
dystonia–parkinsonism (RDP) with a missense mutation in the
Na/K-ATPase 3 subunit (ATP1A3). Asymmetrical parkinso-
nian symptoms evolved over a year. After a stable episode of
another 2.5 years, overnight he developed oromandibular dys-
tonia and more severe parkinsonian symptoms. We conclude
that RDP should be considered as a rare cause of levodopa-
unresponsive parkinsonism even if there is no family history
and the classic presentation is lacking. © 2005 Movement
Disorder Society
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Rapid-onset dystonia–parkinsonism (RDP, DYT12) was ﬁrst
described in 1993.1 It is an autosomal dominantly inherited
disorder, and recently, mutations in Na/K-ATPase 3 subunit
(ATP1A3) on chromosome 19q13 were discovered, implicat-
ing a malfunction of the Na/K pump in familial cases.2 One of
the two sporadic cases described in that study (Patient 1 with
mutation T821C and codon change 1274T) is the subject of the
present study. RDP classically presents with acute-onset dys-
tonia predominantly affecting bulbar musculature and with
additional mild parkinsonian symptoms. Here, we describe a
patient who presented with right-sided parkinsonism develop-
ing gradually over a year. Three and a half years after the onset
of symptoms, sudden parkinsonian and subtle dystonic bulbar
signs appeared.
Case Description
A 39-year-old, right-handed man presented in 1998 with
dragging of the right leg and difﬁculties writing. The symptoms
had progressed insidiously in the course of approximately a
year. Some worsening of symptoms occurred in the course of
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